Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 8Meningioma 2Glioblastoma 2Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Metastatic Digestive System Neuroendocrine Tumor G1 1Medulloblastoma 1Glioma 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Ependymoma 1Disease Progression 1Carcinoid Tumor 1Advanced Lung Neuroendocrine Tumor 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1Adenoma, Islet Cell 1

Interventions

Gemcitabine 26Specimen Handling 20130-nm albumin-bound paclitaxel 18Magnetic Resonance Spectroscopy 13Irinotecan 13Biopsy 12Fluorouracil 11Leucovorin 10Oxaliplatin 9Cyclophosphamide 8pembrolizumab 7fludarabine 7Albumin-Bound Paclitaxel 7Cisplatin 6Cetuximab 6Nivolumab 5durvalumab 4Taxes 4Radiosurgery 4Pemetrexed 4Capecitabine 4zimberelimab 3trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3dehydroftorafur 3aldesleukin 3Radiotherapy 3Immunoglobulin G 3Exercise 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × lutetium Lu 177 dotatate × 30 days × Clear all
NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡